Evidence map›Paper›PMID 40637925›Full record

ArticleCEN case reports2025

Nephrotic syndrome after switching from irinotecan, S-1, and bevacizumab combination to trifluridine/tipiracil.

Jun Takami, Yuta Nakano, Eriko Harada, Shota Nakakuma, Ryosuke Kawamoto, Eisaku Ito, Kayoko Matsukawa

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in CEN case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jun TakamiDepartment of Nephrology, Ome Medical Center, 4-16-5 Higashiome, Ome, Tokyo, 198-0042, Japan.
Yuta NakanoDepartment of Nephrology, Ome Medical Center, 4-16-5 Higashiome, Ome, Tokyo, 198-0042, Japan.
Eriko HaradaDepartment of Nephrology, Ome Medical Center, 4-16-5 Higashiome, Ome, Tokyo, 198-0042, Japan.
Shota NakakumaDepartment of Nephrology, Ome Medical Center, 4-16-5 Higashiome, Ome, Tokyo, 198-0042, Japan.
Ryosuke KawamotoDepartment of Nephrology, Ome Medical Center, 4-16-5 Higashiome, Ome, Tokyo, 198-0042, Japan. kawamoto@kwmt.sakura.ne.jp.ORCID 0009-0007-7006-130X
Eisaku ItoDepartment of Pathology, Ome Medical Center, 4-16-5 Higashiome, Ome, Tokyo, 198-0042, Japan.
Kayoko MatsukawaDepartment of Nephrology, Ome Medical Center, 4-16-5 Higashiome, Ome, Tokyo, 198-0042, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Trifluridine/tipiracil (FTD/TPI) has shown efficacy in treating advanced colorectal and gastric cancers. Although renal injury due to FTD/TPI is rare, its renal effects have not been well documented. We present the case of a 74-year-old man with metastatic colon cancer who developed nephrotic syndrome with hematuria after transitioning from a regimen of irinotecan, S-1, and bevacizumab to FTD/TPI. Renal biopsy revealed IgA nephropathy with glomerular microangiopathy (GMA). His condition improved with steroid therapy. To our knowledge, this is the first documented case of nephrotic syndrome associated with FTD/TPI. Renal toxicity should be monitored through urinalysis during FTD/TPI treatment.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsNephrotic SyndromePyrrolidinesTrifluridineAgedBevacizumabColonic NeoplasmsDrug CombinationsGlomerulonephritis, IGAHematuriaHumansIrinotecanKidneyMaleOxonic AcidTegafurBevacizumabDrug CombinationsIrinotecanOxonic AcidPyrrolidinesS 1 (combination)TegafurThymineTrifluridinetrifluridine tipiracil drug combinationGlomerular microangiopathyIgA nephropathyNephrotic syndromeTrifluridine/tipiracil

Identifiers

PMID40637925
PMCPMC12457258

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.